The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
Thanks Italian. DLI are pioneers in this area and it will interesting to see where they are in say in 2-3 years.
Young.AI is probably just the beginning. Dr Alex Zhavoronko is a prime mover in the longevity sector and
a major 575 shareholder and I am hopeful he will deliver in due course. Rome was not built in a day.
The name change on June 28 signals change and new developments but since then we have had prolonged radio silence
as such I guess something is going on behind the scene.
DVP currently trading at 82c on the old scale with our holding now equaling 29.8% of the MCap - basically shell value
so we could potentially see a major move north if the BoD get it together. As Bignose said it is probably very unrealistic to even dream of the $1b for Fortacin. However, as Dougie pointed out Jones long lasalle determined fair value of PSD502 to be around £167M so that might be the figure the BoD will go after, which should propel us back up to 70c.
Certainly strong headwinds in HK market this year as the Hang Seng index is down 21.2% since the Feb high and 575 tracking the index down. Since Jan Hang Seng is down 7.8%. However, 2022 could well be a rip roarer for emerging markets with 575 benefiting from decent tail winds and progress on all fronts (developing Cu story, DLI and FDA / North America, China and EU progress). I hope Jim and Jamie will hang on to our DVP holding for a while longer, after all they identified this solid high grade Cu play and were both on the board of VXR back in 2013 when Regent held 33.47% of the shares, so they are extremely familiar with the project.
Positive to see DVP powering ahead with our reduced holding now valued @ $17,257,268 (after paying the outstanding ATO bill in full). If we are awarded the Bellevue Gold Ltd (ASX:BGL) u/g mining contract this month we could see a major move north (in the DVP sp). Interesting to see how long ERP's BoD will maintain this key position. Significant upside here with the development of the SS Cu mine, resource upgrade, Cu prices poised to hit $15k/t and the new u/g mining division.
I heard a Swedish pharma Director a few days ago mentioning that many minor pharma companies simply offload their product / company after successfully completing FDA phase 2 to one of the major players. I wonder if this could happen here and possibly explain the prolonged radio silence?
I agree that our DVP holding is not significant in the overall scheme of things,however while we await the long overdue FDA/ /China/EU/operations update it is positive that the value of our holding is growing, and should grow further over the next few weeks and thus significantly underpin our sp.
Upcoming catalysts:
Major SS project status update due on DEC 14 with the assay results from ~25% of the resource and exploration holes drilled during the now completed $10m campaign .
News on the tender for the mining contract at Bellevue Gold’s (ASX: BGL) Bellevue project in Western Australia.
The latest preso from DEC 1 shows Sandvik u/g mining equipment with a DVP sticker so I guess Bill Beament must be fairly confident the first contract will be soon be awarded: https://wcsecure.weblink.com.au/pdf/DVP/02460537.pdf
On the longer track Bill Beament might well be successful in transforming DVP into a multi-billion $ coy, as previously stated, with the new u/g mining division and further progress at SS and beyond.
DVP is heading north again post 5:1 consolidation, now trading at A$3.76 which is 75.2c on the old scale:
https://www2.asx.com.au/markets/company/dvpdb
Our reduced holding is now valued at A$16,221,811 or HK$89.2m which is 25.8% of our current MCap of 33.4m squid.
It seems like DLI is expanding with a few new staff appointments:
Mariya Pankova, iOS Developer - start Sept 2021
?????? ????????, iOS Team Lead - May 2021
Ken Kam, Head of Business Development - Sept 2021
Michelle Keller Senior Manager of Scientific Business Development replaced PM during July 2021
LinkedIn now list 10 current DLI employees incl Alex
Polina Mamoshina is no longer on the list, she left DLI back in June. She mention on LinkedIn that she re-launched
Young.AI app with a 30,000 user base. Not sure if that is a full paying customer base?
I see DLI updated Young.ai 3 times during Sept-Oct (mainly fixing bugs), current version 1.1.6
Hopefully we will see some cash flow from DLI in the short term.
I don't recall Michelle Keller mentioning young-ai during her recent preso, maybe they are taking
a different direction now?
Dr Mike Wyllie is a seasoned pharma professional and he is still about. I believe Mike is doing his utmost to get Fortacin to the market.
Jim, Jamie and Alex have significant skin in the game with +33% of the issued shares and as such they have a major incentive to move the company forward in a big way.
bignose68, you should have moved on many many (as in many) years ago as you obviously don't have any faith in management.
Technology transforming medicine - New Deep Longevity video presentation by DLI senior manager of scientific Business Development Michelle Keller @ STEMulate 2021, an event organized by weareiWiS and STFC UK to amplify female scientific voices. Watch VOD here https://www.youtube.com/watch?v=xli_HpR1mVk
I notice Kenneth Kam was appointed Head of DLI Buisness Development in SEPT.
SP sold down on very low vol.
Wealthy funds are using algorithmic bots to manipulate small cap stocks like 575
to the detriment of mum and dad investors. HKSE market manipulation should be
investigated and prosecuted.
Hang Seng Index down 7% this year mainly generated by the constant interventions from Beijing,
unsettling the HK punters. Not an easy market for ERPG to operate in. The company have clearly
changed strategy from frequent operation updates late last year-early this year to nada, not sure why but hopefully some
news soooooooon.
VXR/DVP holding up fairly well with our reduced holding valued at around AU$13m.
Still hope as Dougie said.
Thanks for sharing Bothwell. Sounds like an e,mail directly from Dr Mike Wyllie. Happy to hold for another 12-18 months to see how this plays out. Heimdal
Not all doom and gloom:
- Return to profit
- Company remains exited about future prospects
- FDA Phase II milestone submission imminent
- Very positive results from marketing study in USA
- Ongoing licensing discussions with potential US partners
- Company pursuing further investments in health and life sciences sectors
- ATO tax bill paid in full
- Manufacturing issues resolved in Europe + significant scale up to 50,000 batch size
- Taiwan launch next month
- China clinical trials start in Oct
- DLI working with several leading insurance companies
- VXR significant increase in value of our holding
- Very low MCap of just GBP 39.8m - significant upside on good news
Heimdal
https://www.scmp.com/week-asia/opinion/article/3143981/hong-kong-equity-investors-may-well-give-and-kiss-hsi-goodbye
Not sure what Jim's game plan is Bignose, interesting times..
Hong Kong equity investors may as well give up and kiss the HSI goodbye:
https://www.scmp.com/week-asia/opinion/article/3143981/hong-kong-equity-investors-may-well-give-and-kiss-hsi goodbye
The Hang Seng Index has now retraced 26% since the FEB 16 high of 31,200.
Index is down 0.21% over the last year, that is in stark contrast to other markets such as:
Nikkei +18%
ASX +22%
CAC + 35%
DOW +26%
FTSE +17%
Hang Seng down 9% during the last month.
https://www.bloomberg.com/markets/stocks
Really really dismal performance and not easy for ERPG to make any meaningful progress with current investor sentiment .
Just wonder how this will play out over the next year or so. Critical for Beijing to step in and steady the ship asap.
Heimdal
At least we had a good start lol. Market was almost flat this morning, then tanked (again). HKSE on par with the exchanges in Egypt and Turkey this year.. down about 10% this year, not performing well at all :-(
Well well well, HK punters luv a divi ;-)
Heimdal
Strong close bouncing off the SMA (50) line. Bring on the dividend!
BUY depth building significantly after lunch Bignose with 2,200,000 in the BID Queue from 16 - 16.9c
and 17c just wiped. Will we see a run this a'noon? Heimdal
Deep Longevity in the news again.
https://www.einnews.com/pr_news/547504208/deep-longevity-releases-an-ai-based-predictor-of-covid-time-to-death
Will be interesting to see where theisDLI work on "AI-based predictor of COVID time-to-death" is heading in these troubled times.
Heimdal
VXR currently trading at 87c with high volume going through, looking very solid Bignose. Some speculation wrt a possible deal at the Diggers and Dealers mining forum - who knows? We might hit AU$1 sooner than we think -> with our holding then valued at AU$29,000,000 or HK$167,000,000!
Very interesting calculations Bignose: 5mill prescriptions. at 100USD/can = 500 mill usd. Brand recognition will probably increase significantly once we hit the US market. Potential for a 10-20 bagger over the next 2-3 years. Charlie should have stayed the course.